Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

STAT+: Pharmalittle: We’re reading about weight loss drug spending, launch prices for medicines, and much more

Top of the morning to you, and a fine one it is. Clear, blue skies and mild breezes are once again enveloping the Pharmalot campus, where the official mascots are happily snoozing in their respective corners. This gives us an opportunity to fire up the coffee kettle and brew still more cups of stimulation. Our choice today is coconut hazelnut, a refreshing change of pace. As always, you are invited to join us. Meanwhile, here are a few items of interest. Hope you have a meaningful and productive day and, of course, do stay in touch. …

Americans are seeing their doctors, getting hospital procedures, and filling prescriptions more frequently than economists and budget experts anticipated, STAT notes. And weight loss drugs, in particular, have morphed into their own special category of spending and are pushing budgets across the country to their limits. The country spent $5.7 trillion on health care in 2025, a 7.3% increase from 2024, according to the latest government figures published in Health Affairs. That amounted to almost $16,500 per person. Federal officials specifically called out prescription drug spending, which soared more than 11% in 2025. 

Drugmakers have found promising new options for one of the most aggressive and hardest-to-treat forms of breast cancer after decades with few breakthroughs, The Wall Street Journal says. Gilead Sciences won Food and Drug Administration approval to sell its drug Trodelvy as a first treatment for newly diagnosed patients with the advanced form of a type of breast cancer known as “triple negative” because it has characteristics that render common treatments ineffective. It is the second such approval in about a month: AstraZeneca and Daiichi Sankyo’s rival drug, Datroway, was approved for a similar group of patients in May.

Continue to STAT+ to read the full story…

​Read More

Published

on

Top of the morning to you, and a fine one it is. Clear, blue skies and mild breezes are once again enveloping the Pharmalot campus, where the official mascots are happily snoozing in their respective corners. This gives us an opportunity to fire up the coffee kettle and brew still more cups of stimulation. Our choice today is coconut hazelnut, a refreshing change of pace. As always, you are invited to join us. Meanwhile, here are a few items of interest. Hope you have a meaningful and productive day and, of course, do stay in touch. …

Americans are seeing their doctors, getting hospital procedures, and filling prescriptions more frequently than economists and budget experts anticipated, STAT notes. And weight loss drugs, in particular, have morphed into their own special category of spending and are pushing budgets across the country to their limits. The country spent $5.7 trillion on health care in 2025, a 7.3% increase from 2024, according to the latest government figures published in Health Affairs. That amounted to almost $16,500 per person. Federal officials specifically called out prescription drug spending, which soared more than 11% in 2025. 

Drugmakers have found promising new options for one of the most aggressive and hardest-to-treat forms of breast cancer after decades with few breakthroughs, The Wall Street Journal says. Gilead Sciences won Food and Drug Administration approval to sell its drug Trodelvy as a first treatment for newly diagnosed patients with the advanced form of a type of breast cancer known as “triple negative” because it has characteristics that render common treatments ineffective. It is the second such approval in about a month: AstraZeneca and Daiichi Sankyo’s rival drug, Datroway, was approved for a similar group of patients in May.

Continue to STAT+ to read the full story…

​Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read